DelveInsight’s, “Parkinson’s Disease Pipeline Insight 2023” report provides comprehensive insights about 140+ companies and 150+ pipeline drugs in Parkinson’s Disease pipeline landscape. It covers the Parkinson’s Disease pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Parkinson’s Disease pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Key Takeaways from the Parkinson’s Disease Pipeline Report
- DelveInsight’s Parkinson’s Disease pipeline report depicts a robust space with 140+ active players working to develop 150+ pipeline therapies for Parkinson’s Disease treatment.
- The leading companies working in the Parkinson’s Disease Market include Cerevel Therapeutics, Inhibikase Therapeutics, Neuraly, Peptron, Biogen, Roche, Brain Neurotherapy Bio, Inc., Modag, Annovis Bio Inc., BioVie Inc., United Neuroscience Ltd., Luye Pharma Group, AbbVie, UCB Biopharma SRL, InnoMedica Schweiz AG, Integrative Research Laboratories AB, H. Lundbeck A/S, Shanghai WD Pharmaceutical Co., Ltd., Cerevance Beta, Inc., Nobilis Therapeutics Inc., BlueRock Therapeutics, Taiwan Mitochondrion Applied Technology Co., Ltd., NeuroDerm Ltd., Pharma Two B, Serina Therapeutics, Sun Pharma Advanced Research Company Limited, CuraSen Therapeutics, Inc., Takeda, Xoc Pharmaceuticals, Sumitomo Pharma Co., Ltd., XWPharma, Athira Pharma, Aptinyx, VistaGen Therapeutics, Inc., 1ST Biotherapeutics, Inc., Novo Nordisk A/S, AstraZeneca, MedImmune, Anavex Life Sciences Corp., Living Cell Technologies, Intra-Cellular Therapies, Inc., Alkahest, Inc., Kissei Pharmaceutical Co., Ltd., and others.
- Promising Parkinson’s Disease Pipeline Therapies in the various stages of development include BIIB122, LY03003, Istradefylline 20 mg or 40 mg, Istradefylline 40 mg, LY3884961, Methylprednisolone, Sirolimus, KM-819, and others.
- March 2023: Neurocrine Biosciences announced a study of phase 2 clinical trials for VY-AADC02. The objectives of this study are to assess the efficacy, safety and tolerability of VY-AADC02 in Patients with Parkinson’s Disease with Motor Fluctuations.
- July 2023: Hoffmann-La Roche announced a study of phase 2 clinical trials for Prasinezumab. This is a multicenter, randomized, double-blind, placebo-controlled study that will evaluate the efficacy and safety of intravenous (IV) prasinezumab versus placebo in participants with Early Parkinson’s Disease (PD) who are on stable symptomatic PD medication.
Request a sample and discover the recent advances in Parkinson’s Disease Treatment Drugs @ Parkinson’s Disease Pipeline Report
In the Parkinson’s Disease pipeline report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Parkinson’s disease collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Parkinson’s Disease Overview
Parkinson’s disease is a progressive disorder that is caused by degeneration of nerve cells in the part of the brain called the substantia nigra, which controls movement. These nerve cells die or become impaired, losing the ability to produce an important chemical called dopamine.
Find out more about Parkinson’s Disease Treatment Drugs @ Drugs for Parkinson’s Disease Treatment
Parkinson’s Disease Emerging Drugs Profile
- Tavapadon: Cerevel Therapeutics
- IkT-148009: Inhibikase Therapeutics
- NLY01: Neuraly
- PT320: Peptron
Parkinson’s Disease Pipeline Therapeutics Assessment
There are approx. 140+ key companies which are developing the Parkinson’s Disease therapies. The Parkinson’s Disease companies which have their Parkinson’s disease drug candidates in the most advanced stage, i.e. phase III include, Cerevel Therapeutics.
Learn more about the emerging Parkinson’s Disease Pipeline Therapies @ Parkinson’s Disease Clinical Trials Assessment
Scope of the Parkinson’s Disease Pipeline Report
- Coverage- Global
- Parkinson’s Disease Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
- Parkinson’s Disease Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
- Parkinson’s Disease Companies- Cerevel Therapeutics, Inhibikase Therapeutics, Neuraly, Peptron, Biogen, Roche, Brain Neurotherapy Bio, Inc., Modag, Annovis Bio Inc., BioVie Inc., United Neuroscience Ltd., Luye Pharma Group, AbbVie, UCB Biopharma SRL, InnoMedica Schweiz AG, Integrative Research Laboratories AB, H. Lundbeck A/S, Shanghai WD Pharmaceutical Co., Ltd., Cerevance Beta, Inc., Nobilis Therapeutics Inc., BlueRock Therapeutics, Taiwan Mitochondrion Applied Technology Co., Ltd., NeuroDerm Ltd., Pharma Two B, Serina Therapeutics, Sun Pharma Advanced Research Company Limited, CuraSen Therapeutics, Inc., Takeda, Xoc Pharmaceuticals, Sumitomo Pharma Co., Ltd., XWPharma, Athira Pharma, Aptinyx, VistaGen Therapeutics, Inc., 1ST Biotherapeutics, Inc., Novo Nordisk A/S, AstraZeneca, MedImmune, Anavex Life Sciences Corp., Living Cell Technologies, Intra-Cellular Therapies, Inc., Alkahest, Inc., Kissei Pharmaceutical Co., Ltd., and others.
- Parkinson’s Disease Pipeline Therapies- BIIB122, LY03003, Istradefylline 20 mg or 40 mg, Istradefylline 40 mg, LY3884961, Methylprednisolone, Sirolimus, KM-819, and others.
Dive deep into rich insights for new drugs for Parkinson’s Disease treatment, Visit @ Parkinson’s Disease Market Drivers and Barriers, and Future Perspective
Table of Content
- Introduction
- Executive Summary
- Parkinson’s Disease: Overview
- Pipeline Therapeutics
- Therapeutic Assessment
- Parkinson’s Disease – DelveInsight’s Analytical Perspective
- Late Stage Products (Phase III)
- Tavapadon: Cerevel Therapeutics
- Drug profiles in the detailed report…..
- Mid Stage Products (Phase II)
- Prasinezumab : Roche
- Drug profiles in the detailed report…..
- Early Stage Products (Phase I)
- MEDI1341: AstraZeneca
- Drug profiles in the detailed report…..
- Preclinical and Discovery Stage Products
- Neural microtissues: Treefrog Therapeutics
- Drug profiles in the detailed report…..
- Inactive Products
- Parkinson’s Disease Key Companies
- Parkinson’s Disease Key Products
- Parkinson’s Disease- Unmet Needs
- Parkinson’s Disease- Market Drivers and Barriers
- Parkinson’s Disease- Future Perspectives and Conclusion
- Parkinson’s Disease Analyst Views
- Parkinson’s Disease Key Companies
- Appendix
For further information on the Parkinson’s Disease pipeline therapeutics, reach out to Parkinson’s Disease Unmet Needs and Analyst Views
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/consulting/ci-tracking